MIM
IMNM icon

Monashee Investment Management’s Immunome IMNM Stock Holding History

Monashee Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-274,861
Closed -$5.9M – 52
2025
Q4 		$5.9M Buy
+274,861
New +$4.82M 3.33% 12
2024
Q2 		– Sell
-132,500
Closed -$3.27M – 102
2024
Q1 		$3.27M Buy
+132,500
New +$2.69M 0.39% 47

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Monashee Investment Management's IMNM Position: Q1 2026 in Review

Monashee Investment Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 274,861 shares — an estimated $5.9M sold.

Monashee Investment Management first reported a position in IMNM in Q1 2024 and held it in 2 quarters. The position peaked at $5.9M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Monashee Investment Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Monashee Investment Management sold 274,861 Immunome shares in Q1 2026, an estimated $5.9M.
  • Monashee Investment Management first reported a position in Immunome in Q1 2024 and held it in 2 quarters.
  • Monashee Investment Management's Immunome position peaked at $5.9M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.